BioVie Secures All Scientific Approvals Needed to Receive Additional 12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID
| BIVI Stock | USD 3.05 0.06 1.93% |
Under 62% of Biovie's investor base is looking to short. The analysis of the overall investor sentiment regarding Biovie Inc suggests that many traders are alarmed. Biovie's investing sentiment shows overall attitude of investors towards Biovie Inc.
Biovie |
Approval from U.S. Army Medical Research and Development Command, Office of Human Research Oversight is the last scientific milestone needed for Company to...
Read at globenewswire.com
 |
Biovie Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Biovie can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Biovie Fundamental Analysis
We analyze Biovie's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biovie using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biovie based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Biovie is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Biovie Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biovie stock to make a market-neutral strategy. Peer analysis of Biovie could also be used in its relative valuation, which is a method of valuing Biovie by comparing valuation metrics with similar companies.
Peers
Biovie Related Equities
| INZY | Inozyme Pharma | 4.46 | ||||
| DAWN | Day One | 2.85 | ||||
| ABOS | Acumen Pharmaceuticals | 2.60 | ||||
| AMLX | Amylyx Pharmaceuticals | 1.54 | ||||
| TERN | Terns Pharmaceuticals | 1.40 | ||||
| MREO | Mereo BioPharma | 1.09 | ||||
| ELDN | Eledon Pharmaceuticals | 1.47 | ||||
| HOOK | Hookipa Pharma | 6.52 | ||||
| XFOR | X4 Pharmaceuticals | 8.11 |
Complementary Tools for Biovie Stock analysis
When running Biovie's price analysis, check to measure Biovie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biovie is operating at the current time. Most of Biovie's value examination focuses on studying past and present price action to predict the probability of Biovie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biovie's price. Additionally, you may evaluate how the addition of Biovie to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |